Cytokine Signalling Forum

CME Courses




« Return to Overview

Developments in Cytokine Signalling

Developed under the auspices of the University of Glasgow supported by an unrestricted educational grant from Pfizer Italia S.r.l.

The use of cytokine inhibitors as a treatment for inflammatory diseases is at the forefront of scientific development and is beginning to be brought from clinical trials into practice. With the approval of tofacitinib in many countries and other agents moving into phase II/III trials, staying on top of current research is a must, especially given the potential benefit to patients. The development of these drugs brings in new targeted therapy and has the potential of great benefit to patients. This course outlines recent developments in cytokine signalling inhibition and show how these developments may come to clinical fruition over the coming years.

By following this programme, you will be able to:

  • Understand the developments in cytokine signalling basic science over the past 12 months
  • Understand and explain the impact these basic science developments will have on clinical developments and practice
This course has been accredited by the EACCME.
Health Awards spring 2015

Module Presenter Video Questions
Introduction
Professor Iain B. McInnes image
Professor Iain B. McInnes

Vice Principal and Head of College of Medical, Veterinary and Life Sciences (MVLS) President of European Alliance of Associations for Rheumatology (EULAR),
University of Glasgow, Glasgow, UK

Professor Iain McInnes is the Vice Principal and Head of College of MVLS in the University of Glasgow, UK. He is also the current President of the EULAR, the leading trans-national society for rheumatology across Europe.

Professor McInnes studied medicine at the University of Glasgow and graduated with honours in 1989 before training in internal medicine and rheumatology. He completed his membership of the Royal College of Physicians (MRCP) in 1992 and became a fellow (FRCP) in 2003. He completed his PhD and post-doctoral studies via fellowships from the Wellcome Trust, the Arthritis Research Campaign (ARC, UK) and the National Institute of Health (NIH) Fogarty Fellowship Programme in both Glasgow and Bethesda, Maryland, USA.

He has extensive experience in leading multicentre programmes, nationally and internationally. Professor McInnes is also Director of the Scottish MRC Clinical Pharmacology and Pathology Clinical PhD Training Programme; Chief Investigator for the Scottish Early RA Cohort (SERA) and the related SMS-IC biomarker discovery programme (PROMISERA); and Chief Investigator of numerous global phase II and III clinical trials of novel immune therapies

His major interest is in the biology of inflammatory synovitis in rheumatoid arthritis, psoriatic arthritis and septic arthritis. He operates on a translational science programme in which state of the art cellular and molecular biology techniques are applied to elucidate the mechanisms underlying the perpetuation of a range of chronic diseases seeking to build precision medicine approaches and new therapeutics thereafter. He received the Sir James Black Prize Medal, a prestigious award in medicine in 2016 by the Royal Society of Edinburgh for his outstanding contribution to the field of immunology. In 2019, Professor McInnes was awarded a CBE for his services to Medicine.

Prof. Iain B. McInnes (Bio)
02:13
Cytokine signalling and Jak inhibitors: Theory, Practice and Prospects
Professor John J. O'Shea image
Professor John J. O'Shea

Director, NIAMS Intramural Research Program,
NIAMS, Bethesda, Maryland, USA

John J. O'Shea, M.D., graduated Phi Beta Kappa with a Bachelor of Science degree from St. Lawrence University, and received a Doctor of Medicine degree from the University of Cincinnati. He then served as an intern and resident in Internal Medicine at the State University of New York Upstate Medical University in Syracuse, New York. Dr O'Shea joined the National Institutes of Health (NIH) in 1981 for subspecialty training in Allergy and Immunology in the National Institute of Allergy and Infectious Diseases. He did additional postdoctoral work in the Cell Biology and Metabolism Branch in the National Institute of Child Health and Human Development. Dr O’Shea is board certified in Internal Medicine and Allergy and Immunology.

He moved to the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) in 1994 as Chief of the Lymphocyte Cell Biology Section of the Arthritis and Rheumatism Branch. He was appointed Chief of the Molecular Immunology and Inflammation Branch in 2002, and became Scientific Director and Director of the NIAMS Intramural Research Program in 2005.

Dr O'Shea has served on the editorial boards of multiple journals, including: Immunity, Journal of Experimental Medicine, Journal of Biological Chemistry, Journal of Immunology, and Blood. He has been an invited lecturer at numerous universities and international meetings in the U.S., Canada, Europe and Asia.

Dr O'Shea has authored more than 225 articles. His area of scientific interest is cytokine signal transduction, dissecting the role of Jaks and Stats family transcription in immunoregulation. Dr O'Shea and his colleagues cloned the tyrosine kinase, JAK3, and demonstrated its role in pathogenesis of severe combined immunodeficiency.

Prof. John J. O'Shea (Bio)
30:24 10
Kinase targeting in rheumatoid arthritis: Clinical data overview
Professor Iain B. McInnes image
Professor Iain B. McInnes

Vice Principal and Head of College of Medical, Veterinary and Life Sciences (MVLS) President of European Alliance of Associations for Rheumatology (EULAR),
University of Glasgow, Glasgow, UK

Professor Iain McInnes is the Vice Principal and Head of College of MVLS in the University of Glasgow, UK. He is also the current President of the EULAR, the leading trans-national society for rheumatology across Europe.

Professor McInnes studied medicine at the University of Glasgow and graduated with honours in 1989 before training in internal medicine and rheumatology. He completed his membership of the Royal College of Physicians (MRCP) in 1992 and became a fellow (FRCP) in 2003. He completed his PhD and post-doctoral studies via fellowships from the Wellcome Trust, the Arthritis Research Campaign (ARC, UK) and the National Institute of Health (NIH) Fogarty Fellowship Programme in both Glasgow and Bethesda, Maryland, USA.

He has extensive experience in leading multicentre programmes, nationally and internationally. Professor McInnes is also Director of the Scottish MRC Clinical Pharmacology and Pathology Clinical PhD Training Programme; Chief Investigator for the Scottish Early RA Cohort (SERA) and the related SMS-IC biomarker discovery programme (PROMISERA); and Chief Investigator of numerous global phase II and III clinical trials of novel immune therapies

His major interest is in the biology of inflammatory synovitis in rheumatoid arthritis, psoriatic arthritis and septic arthritis. He operates on a translational science programme in which state of the art cellular and molecular biology techniques are applied to elucidate the mechanisms underlying the perpetuation of a range of chronic diseases seeking to build precision medicine approaches and new therapeutics thereafter. He received the Sir James Black Prize Medal, a prestigious award in medicine in 2016 by the Royal Society of Edinburgh for his outstanding contribution to the field of immunology. In 2019, Professor McInnes was awarded a CBE for his services to Medicine.

Prof. Iain B. McInnes (Bio)
35:09 10
Evaluation 4

Date of preparation: April 2014